Physician profile
Daniel E Viders
NPI 1558354407
$7,081.17
in general payments reported to CMS, 2019-2025
27 companies · $509 in 2025
The $509 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $862 · 2021: $1,229 · 2022: $1,398 · 2023: $1,613 · 2024: $935 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,056.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,379.83 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $894.65 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $650.21 | 2019-2025 | Dupixent |
| Genzyme Corporation | $629.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $626.74 | 2019-2023 | |
| Janssen Biotech, INC. | $597.65 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $358.62 | 2019-2025 | Adbry |
| Lilly USA, LLC | $329.29 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $300.10 | 2020-2024 | Ilumya, Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $220.36 | 2023 | Vtama |
| Ucb, INC. | $178.58 | 2019-2023 | Bimzelx, Cimzia |
| Incyte Corporation | $175.81 | 2021-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $148.81 | 2022-2023 | Sotyktu |
| Pfizer INC. | $135.56 | 2021-2024 | |
| Celgene Corporation | $88.89 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $80.76 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $45.05 | 2024 | Zoryve |
| Galderma Laboratories, L.P. | $41.80 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.31 | 2020 | |
| Mission Pharmacal Company | $27.65 | 2019 | |
| Strata Skin Sciences, INC. | $24.37 | 2019-2021 | |
| Lnhc, INC | $23.79 | 2025 | Zelsuvmi |
| Dermira, INC. | $21.77 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.72 | 2023 | Cyltezo |
| Glaxosmithkline, LLC. | $14.74 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.70 | 2024 | Nuzyra |
| Sandoz INC. | $13.94 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Viders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.